HSR21-070: Feasibility of Tracking Digital Activity, Sleep, and Patient-Reported Outcomes (PROs) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Undergoing an In-Class Transition From Parenteral Bortezomib-Based Therapy to Oral Ixazomib-Lenalidomide-Dexamethasone (IRd) in the Ongoing Community-Based United States (US) MM-6 Study (NCT03173092)

Authors: Kirsten Stuber MSN, MBA, FNP-BC, AOCNP 1 , Habte A. Yimer MD 1 , Karin Choquette MSN, AGNP-C, CCRC 2 , Sudhir Manda MD, FACP 2 , Jennifer Clayton MSN, ACNP 3 , Saulius Girnius MD 3 , Joshua Richter MD 4 , Presley Whidden MS 5 , Kimberly Bogard PharmD, BCPS 5 , Dasha Cherepanov PhD 5 and Stephen J. Noga MD, PhD 5
View More View Less
  • 1 Texas Oncology - Tyler/US Oncology Research, Tyler, TX
  • 2 Arizona Oncology, Tucson, AZ
  • 3 Trihealth Cancer Institute, Cincinnati, OH
  • 4 Tisch Cancer Institute: Icahn School of Medicine at Mount Sinai, New York, NY
  • 5 Millennium Pharmaceuticals, Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
Restricted access

Corresponding Author: Kirsten Stuber, MSN, MBA, FNP-BC, AOCNP